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SLEAbstract Aim of the work: SLE is an autoimmune disease characterized by a variety of clinical
and laboratory abnormalities. It may affect many organs and pulmonary involvement is a common
ﬁnding in SLE. The purpose of this study was to disclose the pulmonary involvement in early SLE
patients not more than 2 years of disease duration using the computed tomography (CT) as well as
the pulmonary function tests as ways of pulmonary involvement assessment.
Patients and methods: Forty-two patients aged 29 ± 12.5 with early SLE not more than 2 years
of disease duration were recruited for the study. All patients were assessed clinically for their SLE
with BILAG which was utilized for disease activity determination.
Results: Nine and half percent of our patients were found to be clinically involved by ILD,
where 28.6% have abnormal HRCT ﬁnding, 26.2% with abnormal PFT. Variants that were asso-
ciated with an abnormal forced vital capacity FVC < 80% in a signiﬁcant manner were: smoking,
long disease duration, self-reported pulmonary symptoms (p 0.001), BILAG global score (p 0.006),
Anti dsDNA (p 0.001), Antiphospholipid (IgM or IgG) (p 0.01), anti Sm (p 0.002), anti-RNP (p
0.005), HRCT abnormalities (p 0.001), current medication of steroid (any dose) (p 0.005), immuno-
modulator therapy (p 0.002), and Rituximab therapy (p 0.001).
Conclusions: ILD occurs as early as in the ﬁrst 2 years in the course of SLE patients. There was a
clear predilection of ILD with certain variables in our cohort of patients.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a connective tissue
disease characterized by the formation of autoantibodies and
immune complexes [1–3]. It is an autoimmune disease charac-
terized by a variety of clinical and laboratory abnormalities. It
may affect many organs and pulmonary involvement is a com-
mon ﬁnding in SLE [4] (see Figs. 1 and 2).
Figure 2 HRCT of lung window of lower lung zone in an early
SLE patient revealed: ground glass appearance of anterior
segment of right lower lobe.
226 H.M. Habib et al.Pleuro-pulmonary manifestations are present in almost half
of the patients during the disease course and may be the pre-
senting symptoms in 4–5% of patients with SLE. Complica-
tions directly associated to the disease include pleuritis with
or without pleural effusion, alveolitis, interstitial lung disease,
lupus pneumonitis, pulmonary hemorrhage, pulmonary arte-
rial hypertension, and pulmonary thromboembolic disease.
Complications due to secondary causes include pleuro-pul-
monary manifestations of cardiac and renal failure, atelectasis
due to diaphragmatic dysfunction, opportunistic pneumonia,
and drug toxicity [5–7].
High resolution computed tomography (HRCT) and pul-
monary function tests (PFTs) are the most frequent investiga-
tion tools used for the detection and follow up of lung
involvement in SLE [8,9]. HRCT is more sensitive than PFTs
or chest X-ray (CXR) in the evaluation of pleuropulmonary
disease in SLE [10].
Many articles have studied the lung involvement in systemic
lupus erythematosus, yet sparse works explore how early the
pulmonary involvement happens in the natural course of SLE.
The aim of the present study is to reveal the pulmonary
involvement in early systemic lupus erythematosus patients
with not more than 2 years of disease duration using HRCT
together with PFTs as tools of pulmonary involvement
assessment.
2. Patients and methods
Forty-two patients with early SLE not more than 2 years of
disease duration who were fulﬁlling the American College of
Rheumatology (ACR) classiﬁcation criteria for SLE [11] were
recruited for the study in the period from January 2010 to
January 2013.
Disease duration at enrollment was deﬁned as duration
from the date of physician diagnosis until the date at ﬁrst study
visit. An informed consent was obtained for every patientFigure 1 HRCT of lung window of lower lung zone in an early
SLE patient revealed: left pleural effusion, bilateral basal ﬁne sub-
pulmonary thin septation with minimal small cystic changes.participating. Mean duration of disease was 20 ± 4 months.
Patients with a previous diagnosis of another connective tissue
disorder which may associate SLE such as rheumatoid arthri-
tis, primary Sjo¨gren’s syndrome, mixed connective tissue dis-
ease, systemic sclerosis, antiphospholipid antibody syndrome
or idiopathic inﬂammatory myositis were excluded from this
study. Presence or absence of pulmonary symptoms is not
considered as exclusion or inclusion criteria for patient’s
enrollment in the study. The study was approved by the local
ethics committee of the hospital (Al Ahsa hospital, Al-Ahsa,
Eastern District of KSA) and written consents were provided
by the included patients.
2.1. Clinical assessment
Thorough history taking and full clinical examination were
done for all patients including medication history. All the
patients were subjected to overall clinical assessment and
disease activity assessment was performed using the BILAG
(British Isles Lupus Assessment Group) disease activity in-
dex [12]. It distinguishes activity in 8 organs or systems
namely general, mucocutaneous, central nervous system,
musculoskeletal, cardio-vascular system/respiratory, vasculi-
tis, renal and hematological systems. It provides an accurate
means of grading disease activity from the ‘‘most active’’ to
‘‘no evidence of disease activity currently’’. Patients are clas-
siﬁed to 5 grades: A = 9 points, B = 3 points, C = 1 point,
D = 0 point, and E = 0 point. Full clinical chest examina-
tion was done to ﬁnd out any symptoms or signs suggestive
of interstitial lung disease (ILD).
2.2. Laboratory tests
The following laboratory tests were evaluated: full blood
count, erythrocyte sedimentation rate (ESR), C-reactive
Table 1 Demographic and clinical characteristics of the
systemic lupus erythematosus (SLE) patients.
Variable SLE patients (n= 42)
Age 29 ± 12.5
Gender (female/male) (% female) 37/5 (88% Female)
Smoking No. (%) 3 (7.1)
Disease duration (months) 20 ± 4
Self-reported pulmonary symptoms
Dyspnea No. (%) 8 (11.9)
Pleuritic chest pain No. (%) 14 (33.3)
BILAG global score 10 ± 3.8
Medications: No. (%)
NSAIDs 21 (50)
Steroid (any dose) 37 (88)
Hydroxychloroquine 33 (78.5)
Immunomodulatora 38 (90.5)
Rituximab 2 (4.7)
BILAG, British Isles Lupus Assessment Group; NSAIDs, non-
steroidal anti-inﬂammatory drugs.
a Immunomodulator, any of azathioprine, mycophenolate mofe-
til, methotrexate, cyclophosphamide.
Table 2 Autoantibody proﬁle among the systemic lupus
erythematosus (SLE) patients.
Autoantibody seropositivity No. (%) SLE patients (No = 42)
ANA 41 (97.5)
Anti dsDNA 27 (64)
Anti-Ro 11 (26)
Anti-La 10 (23.8)
APL (IgM or IgG) 12 (28.5)
Anti-Sm 10 (23.8)
Anti- RNP 9 (21.5)
SLE, systemic lupus erythematosus; ANA, antinuclear antibody;
dsDNA, double stranded deoxyribonucleic acid; APL, anti-
phospholipid; Ig, immunoglobulin; Sm, Smith; RNP,
ribonucleoprotein.
Lung involvement of SLE 227protein (CRP), and total hemolytic complement activity
(CH50). Auto-antibodies were screened at the base line visit
and included each of the following: antinuclear antibody
(ANA), anti-Ro, anti-La, Anti-phospholipid (IgM, IgG),
anti-Smith (anti-Sm), anti-ribonucleoprotein (anti-RNP), and
anti-double stranded Deoxyribonucleic acid (anti-dsDNA).
The ANA was measured using immunoﬂuorescence; antibod-
ies to dsDNA were measured by enzyme linked immunosor-
bent assay (ELISA) or Farr assay. Testing for extractable
nuclear antigens (anti-Ro, anti-La, anti-Sm and anti-RNP)
was done by ELISA followed by a conﬁrmatory immunoblot.
Seropositivity was deﬁned as one or more positive assays for
that particular antibody measured at any point during a pa-
tient’s disease course. Clinical laboratory tests were performed
according to standard hospital laboratory procedures.
2.3. Pulmonary function tests (PFT)
All patients enrolled in the study were subjected to pulmonary
function tests within not more than 2 months from radiologi-
cal evaluation. The tests included spirometry and diffusion
capacity for carbon monoxide (DLCO). Spirometry was per-
formed according to the American Thoracic Society standards
[13]. The DLCO was determined with the single breath method
according to the American Thoracic Society standards [14].
Actual results of PFT are expressed as the percentage of pre-
dicted values. DLCO values were corrected for hemoglobin
concentrations according to the formula proposed by Burgess
et al. [15] to obtain DLCO values under standard conditions.
An abnormal PFT was deﬁned as <80% predicted forced
vital capacity (FVC), <80% predicted DLCO, or a Forced
expiratory volume in 1 s (FEV1) divided by FVC (FEV1/
FVC) ratio of <70% predicted; restrictive physiology on
PFT was considered a VC of <80% predicted [13]. Measure-
ments were obtained without bronchodilator administration
with subjects tested in the sitting position.
2.4. Computerized tomography (CT) assessment
The CT scans were obtained with Philips machine one slice.
Continuous scans were obtained with 1–1.5 mm collimation
and were reconstructed with high spatial-frequency algorithm.
They were obtained at suspended end-inspiratory effort with
the patient in supine position and without intravenous material.
The features of interstitial lung disease by HRCT included
septal lines, reticulations, traction bronchiectasis, cyst forma-
tion, and ground glass appearance. Patients were considered
to have ILD if there were reticular and/or interstitial opacities
with or without ground glass opacities and/or honeycombing
on the chest CT scan after excluding alternative etiologies
for the ILD [16]. Pleural involvement on chest imaging was de-
ﬁned as the presence of pleural effusions, pleural thickening, or
pleural ﬁbrosis on CXR or CT scan.
Statistical analysis: Data variables were encoded and en-
tered into computer and data cleaning was performed. All data
were described in the form of number, percent, mean, and
standard deviation. Univariate analysis was performed to cal-
culate the Odds ratio and conﬁdence interval. Chi-square test
was used for comparison of categorical data, while Stu-
dent’s-t-test was performed to compare quantitative data. p
Value was level of signiﬁcance was set at p< 0.05. Data entryand statistical analysis were performed using the Statistical
Package for Social Science (SPSS) version 15.0 (SPSS Inc.,
Chicago, Illinois).
3. Results
3.1. Study population
Demographic and clinical characteristics of the patients are
summarized in Table 1. The study group comprised 42 patients
with a mean age of 29 ± 12.5 years that ranged from 16.5 to
45.5 years. Only one female patient was diagnosed as juvenile
SLE, and her morphologic and serologic phenotypes were
identical with those of the adult form, thus abolishing its effect
being juvenile form of SLE. Thirty-seven patients were females
and 5 were males, with 3 smokers in our cohort. Mean disease
duration was 20 ± 4 (range 4–24) months. Past history of pa-
tients revealed none had chronic respiratory symptoms. At the
Table 3 Pulmonary involvement in SLE patients as detected
by pulmonary function tests (PFTs), high resolution comput-
erized tomography (HRCT) chest and pulmonary clinical
manifestations.
Mode of detection No. (%)
Abnormal pulmonary ﬁndings in the SLE patients (No. = 42)
High resolution computerized tomography (HRCT) 12 (28.6)
Pulmonary function tests (PFT) 11 26.2)
With ﬁndings in HRCT 7 (16.7)
Without ﬁndings in HRCT 4 (9.5)
HRCT and PFT with clinical manifestations of ILD 4 (9.5)
Total No. of aﬀected patients 18 (42.9)
ILD, interstitial lung disease.
228 H.M. Habib et al.time of examination, 8 patients were having dyspnea, while 14
complained of pleuritic chest pain. For disease activity in our
patients, mean BILAG global score was 10 ± 3.8 (range 0–
21). The medications given to the patients of the present study
are also mentioned in Table 1.
3.2. Autoantibody proﬁle among patients
Table 2 summarized the number and the percentage of autoan-
tibody proﬁle among our cohort of early SLE patients.
3.3. Lung involvement in patients
Out of the 42 SLE patients, 4 (9.52%) were found to have clin-
ical symptoms and signs with abnormal PFT and HRCTTable 4 Univariate analysis of factors associated with an abnorm
erythematosus.
Variable Odds ratio
Clinical characteristics
Age 2.32
Gender 0.91
Smoking 2.34
Disease duration 0.99
Self-reported pulmonary symptoms 4.23
BILAG global score 2.22
Autoantibody proﬁle
ANA 1.10
Anti dsDNA 2.99
Anti Ro 0.88
Anti La 0.73
APL (IgM or Ig G) 2.34
Anti Sm 3.58
Anti-RNP 4.43
HRCT chest abnormalities 1.37
Current medications
NSAIDs 1.66
Steroid (any dose) 2.95
Hydroxychloroquine 1.66
Immunomodulator therapy 2.01
Rituximab 3.11
BILAG, British Isles Lupus Assessment Group; ANA, antinuclear ant
phospholipid; Ig, immunoglobulin; Sm, Smith; RNP, ribonucleoprotein
steroidal anti-inﬂammatory drugs.related to ILD. The total number of pulmonary involvement
was 18 (45%), detected by clinical manifestations of ILD,
abnormal PFT and/or HRCT ﬁndings. Twelve (28.57%) pa-
tients showed abnormal ﬁndings in HRCT (mainly in lower
lung lobe, including reticular and/or interstitial opacities with
or without ground glass opacities and/or honeycombing).
Two patients showed blunting of costo-phrenic angle (denot-
ing pleural effusion) in CXR, without any radiological ﬁnding
of ILD. Eleven patients (26.19%) showed abnormalities in
their PFT. Only 2 patients (4.76%) showed obstructive venti-
latory dysfunction (FEV1 68.5 ± 11.5) while a restrictive ven-
tilatory dysfunction was present in 9 (21.42%) as the mean VC
was 66 ± 12. Ten patients (23.8%) showed diffusion involve-
ment with a mean DLCO of 68.5 ± 13. Out of the 11 patients
with abnormal PFT, 7 (16.66% of total number of patients)
patients also had abnormal HRCT ﬁndings. Table 3 illustrates
these results.
3.4. Clinical interrelationships
Tables 4 and 5 show univariate analysis of factors associated
with an abnormal forced vital capacity and abnormal high res-
olution computerized tomography, respectively, in patients
with early systemic lupus erythematosus. Demographic fea-
tures, Clinical manifestations, autoantibody proﬁle, HRCT
chest abnormalities and forced vital capacity abnormalities
(alternatively and respectively) and current medications were
correlated with an abnormal FVC and abnormal HRCT
(respectively) among the study population. Variants that were
signiﬁcantly associated with an abnormal FVC (<80%) and
abnormal HRCT were found to be identical with exceptional forced vital capacity in patients with early systemic lupus
95% Conﬁdence interval p-Value
0.6–10.33 0.3
0.94–1.13 0.5
0.93–4.11 0.05
2.03–2.13 0.03
1.36–7.67 0.001
2.00–2.53 0.006
0.34–3.33 0.1
0.93–9.01 0.001
0.43–2.78 0.2
0.19–3.07 0.1
0.88–8.37 0.01
2.13–11.43 0.002
1.89–12.51 0.005
1.03–2.37 0.001
0.32–3.82 0.1
1.67–8.33 0.005
0.32–3.82 0.3
1.09–12.35 0.002
1.11–8.33 0.001
ibody; dsDNA, double stranded deoxyribonucleic acid; APL, anti-
; HRCT, high resolution computerized tomography; NSAIDs, non
Table 5 Univariate analysis of factors associated with abnormal high resolution computerized tomography (HRCT) in patients with
early systemic lupus erythematosus.
Variable Odds ratio 95% Conﬁdence interval p-Value
Clinical characteristics
Age 2.12 0.7–9.83 0.2
Gender 1.01 0.97–1.19 0.6
Smoking 2.54 0.95–4.18 0.05
Disease duration 0.91 2.13–2.19 0.04
Self-reported pulmonary symptoms 4.11 1.21–8.07 0.002
BILAG global score 1.99 1.80–2.59 0.005
Autoantibody proﬁle
ANA 1.22 0.44–3.43 0.2
Anti dsDNA 3.22 0.83–9.11 0.003
Anti Ro 0.87 0.33–2.18 0.1
Anti La 0.83 0.11–2.97 0.2
APL (IgM or Ig G) 2.31 0.99–8.77 0.05
Anti Sm 4.08 2.23–10.43 0.003
Anti-RNP 1.42 0.81–3.41 0.06
Forced vital capacity abnormalities 1.44 1.01–2.65 0.002
Current medications
NSAIDs 1.64 0.37–3.92 0.2
Steroid (any dose) 2.85 1.77–7.93 0.003
Hydroxychloroquine 1.56 0.22–3.92 0.2
Immunomodulator therapy 2.11 1.19–12.25 0.001
Rituximab 2.89 1.21–7.33 0.001
BILAG, British Isles Lupus Assessment Group; ANA, antinuclear antibody; dsDNA, double stranded deoxyribonucleic acid; APL, anti-
phospholipid; Ig, immunoglobulin; Sm, Smith; RNP, ribonucleoprotein; NSAIDs, non-steroidal anti-inﬂammatory drugs.
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RNP (p 0.06). Variants that were signiﬁcantly associated with
an abnormal FVC (<80%) were smoking, long disease dura-
tion, self-reported pulmonary symptoms (p 0.001), BILAG
global score (p 0.006), Anti dsDNA (p 0.001), Anti-phospho-
lipid (IgM or IgG) (p 0.01), anti Sm (p 0.002), anti-RNP (p
0.005), HRCT abnormalities (p 0.001), current medication of
steroid (any dose) (p 0.005), immunomodulator therapy (p
0.002), and Rituximab therapy (p 0.001). Variants that were
signiﬁcantly associated with an abnormal HRCT were smok-
ing (p 0.05), long disease duration (p 0.04), self-reported pul-
monary symptoms (p 0.002), BILAG global score (p 0.005),
Anti dsDNA (p 0.003), Anti-phospholipid (IgM or IgG) (p
0.05), anti Sm (p 0.003), anti-RNP (p 0.001), FVC abnormali-
ties (p 0.002), current medication of steroid (any dose) (p
0.003), immunomodulator therapy (p 0.001), and Rituximab
therapy (p 0.001).4. Discussion
Respiratory symptoms and abnormal lung function are rela-
tively common in SLE. There have been many studies concern-
ing pulmonary involvement in patients with SLE. Most of
these studies relied upon the characteristics of PFT and HRCT
for picking up abnormal lung function in this sector of the pa-
tients [10,17,18]. Therefore; we attempted to assess the lung
involvement through PFT and HRCT in early diagnosed
SLE patients and correlate this involvement with clinical and
immunological proﬁle in patients. This was considered with
intension for revealing how early SLE patients have their lunginvolved, and tried to correlate the involvement with multiple
patient’s variants. Pulmonary involvement in patients with
SLE depending upon HRCT as well as lung physiology studies
has been addressed in a wide range of reports. These reports
have denoted evident proven ﬁndings; yet little have been ad-
dressed for early SLE disease [7,19,20]. Emerging data of our
results emphasized that 9.5% of our early SLE patients have
deﬁnitive lung involvement as detected by clinical manifesta-
tions of ILD as well as abnormalities of the PFTs and HRCT
chest. A total of 42.9% of the studied patients had an element
of pulmonary involvement as detected by PFT and HRCT;
these patients may develop ‘‘manifest’’ ILD in due course of
their SLE disease. Of note that, one of our patients was of
juvenile SLE variety. Her morphological, serological charac-
ters were not differentiated with adult form, and her results
cannot be relied upon for differentiation pulmonary involve-
ment between adult and juvenile forms. Further longitudinal
study may be required to follow up those patients to detect
any clinical manifestation of conversion to clinically ‘‘mani-
fest’’ ILD.
In comparison to our ﬁndings, Nakano et al. found that
impairment of DLCO was frequently observed in SLE patients
who had no clinical respiratory abnormalities and that no sig-
niﬁcant correlation was found between impairment of DLCO
and disease activity of SLE. DLCO was reduced in 47% of their
patients and a restrictive impairment of PFT was observed in
8%. The prevalence of pulmonary ﬁbrosis was 13% [21].
However, Silberstein et al. showed that pulmonary abnormal-
ities do not correlate with immune parameters of their cohort
[22]. Conﬂicting results have been published concerning the
correlation among HRCT ﬁndings, pulmonary symptoms,
230 H.M. Habib et al.and physiologic studies in SLE patients. One prospective study
of 34 patients with SLE found abnormalities detected by
HRCT, pulmonary function studies, or chest radiography in
70, 41, and 24 percent, respectively [23]. No correlation existed
among HRCT, pulmonary function studies, and pulmonary
symptoms. In contrast, another prospective study of 48 pa-
tients found that abnormalities on HRCT were associated with
symptom duration and pulmonary function abnormalities [24].
We have analyzed factors associated with an abnormal
forced vital capacity as well as HRCT in patients with early
SLE. Notably, an abnormal FVC and HRCT were detected in
a sector of our cohort. In both abnormal FVC andHRCT, a sig-
niﬁcant correlation was found with smoking, disease duration,
self-reported pulmonary symptoms, BILAG score, Anti
dsDNA, Anti-phospholipid (IgM or Ig G), anti Sm, HRCT
abnormalities, current medication of steroid (any dose), Immu-
nomodulator therapy, and Rituximab therapy. However, anti-
RNP was found to be signiﬁcantly correlated with abnormal
FVC but not with abnormal HRCT which may need further
work for clariﬁcation and explanation. These variants can be
considered as ‘‘predictors’’ for poor pulmonary involvement in
SLE patients andmay be related to forthcoming aggressive lung
disease. There are not enough reports addressing factors associ-
atedwith anabnormal forced vital capacity in patientswith early
SLE. Our results are in agreement with Allen et al. [9] who re-
ported FVC < 80% among factors that were associated with
increasing disease duration, the presence of dyspnea, pleuritic
chest pain, a history of pleuritis, total systemic lupus activity
measure score, seropositivity for anti-dsDNA, anti-Sm, anti-
RNP, current use of prednisone, and current use of hydroxy-
chloroquine and a trend toward a signiﬁcant association be-
tween pleural involvement on chest imaging and an abnormal
FVC.Of note that their cohort of patients is not selected as early
SLE patients, yet this was found to be very close to our results
and ascertained those variables as predictors for aggressive lung
disease in coming future in SLEpatients. Longitudinal followup
studies are needed to trace those variables in patients with early
SLE during their disease course.
It can be concluded that ILD occurs as early as in the
ﬁrst 2 years in the course of SLE patients. There was a clear
predilection of ILD with certain variables in our cohort of
patients which may be considered as predictors for forth-
coming aggressive lung disease which needs further work.
Many articles have explored the pulmonary involvement in
SLE patients by different means, yet few were found to dis-
close this involvement as early as the ﬁrst 2 years of illness.
In this view, we still miss much data to compare our ﬁnd-
ings with and need further studies with a wider sample size
to conﬁrm the present results. Furthermore, a longitudinal
study is needed to verify our data regarding disease activity
correlation with incidence of early pulmonary involvement in
SLE disease course.Disclosure statement
The authors disclose no conﬂict of interest.
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